In vitro inhibitory effect of SR 27417, a potent platelet-activating factor (PAF) receptor antagonist, on the PAF-induced bovine platelet aggregation

Veterinary Research

Volumn 31, Issue 2, 2000, Pages 267-272

  Silva, Miriam Bastos Da ^a   Delaunois, Annie ^a   Gustin, Pascal ^a   Godeau, Jean Marie ^a   Lekeux, Pierre ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Bovine; Platelet; Platelet aggregation; Platelet activating factor (PAF); SR 27417

Indexed keywords

APAFANT; FOROPAFANT; THROMBOCYTE ACTIVATING FACTOR; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CATTLE; CATTLE DISEASE; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; HEMOSTASIS; INFLAMMATORY DISEASE; NONHUMAN; RESPIRATORY TRACT DISEASE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTOPENIA; THROMBOSIS;

ANIMALIA; BOS TAURUS; BOVINAE;

EID: 0034120826     PISSN: 09284249     EISSN: None     Source Type: Journal    
DOI: 10.1051/vetres:2000115     Document Type: Article

References (39)

1. Argiolas L., Fabi F., Del Basso P., Mechanisms of pulmonary vasoconstriction and bronchoconstriction produced by PAF in the guinea-pig: role of platelets and cyclo-oxygenase metabolites, Br. J. Pharmacol. 114 (1995) 203-209.
2. Bastos da Silva M., Herion F., Raskinet R., David J-L., Gustin P., Dessy C., Lekeux P., Inhibition of PAF-induced platelet aggregation by WEB 2086 in vitro, an antagonist to the receptor for platelet-activating factor, in bovine, J. Vet. Med. A 43 (1996) 399-413.
3. Bastos da Silva M., Gustin P., Herion F., Raskinet R. David J.-L., Gougnard T., Plomteux G., Desmecht D., Lekeux P., The effect of intravenous administration of WEB 2086 on PAF-induced platelet aggregation in health Friesian calves, Vet. Res. Commun. 21 (1997) 521-531.
4. Bastos da Silva M., Dessy C., David J.-L., Lekeux P., Morphological alterations of blood platelets induced by platelet activating factor (PAF) and partial inhibition by ketiprofen in calves, Vet. Res. 28 (1997) 489-502.
5. Bastos da Silva M., Gustin P., Herion F., David J.-L., Van De Weerdt M.L., Lekeux P., Effect of ketoprofen on PAF-induced bovine platelet aggregation, Vet. J. 155 (1998) 201-203.
6. Bernart A., Herbert J.-M., Salel V., Lespy L., Maffrand J.P., Protective effect of SR 27417, a novel PAF antagonist, on PAF or endotoxin-induced hypotension in the rat and the guinea-pig, J. Lipid. Mediators 51 (1992) 41-48.
7. Bernart A., Herbert J.-M., Effect of various drugs on adriamycin-enhanced venous thrombosis in the rat: importance of PAF, Thromb. Res. 75 (1994) 91-97.
8. Bondy G.S., Gentry P.A., Characterization of the normal bovine platelet aggregation response, Comp. Biochem. Physiol. C92 (1989) 67-72.
9. Born G.V.R., Quantitative investigations into the aggregation of blood platelets, J. Physiol. (Lond.) 162 (1962) 67.
10. Braquet P., Godfroid J.J., PAF-acether binding sites: 2 designers of specific antagonists,Trends Pharmacol. Sci. 7 (1986) 397-403.
11. Braquet P., Touqui L., Shen T.Y., Vargaftig, B.B., Perspectives in platelet-activating factor research, Pharmacol. Rev. 39 (1987) 97-145.
12. Casals-Stenzel J., Weber K.H., Triazolodiazepines: dissociation of their PAF (platelet-activating factor) antagonistc and CNS activity, Br. J. Pharmacol. 90 (1987) 139-146.
13. Chan W.P., Levy J.V., Effects of antiplatelet agents on platelet aggregation induced by platelet-activating factor (PAF) in human whole blood, Prostaglandins 42 (1991) 337-342.
14. 1, Can. J. Vet. Res. 62 (1998) 1-8.
15. Chignard M., Le Couedic J.P., Tencé M., Vargaftig B.B., Benveniste J., The role of platelet-activating factor in platelet aggregation, Nature (London) 279 (1979) 799-800.
16. Collins L.C., Roberts A.M., Effects of platelet-activating factor on arteriolar and venular tone in rat trachea, Microvasc. Res. 53 (1997) 63-72.
17. Foster A.P., Cunningham F.M., Andrews M.J., Lees P., A comparison of the action of platelet-activating factor (PAF) antagonists WEB 2170 and 2086 in the horse, J. Vet. Pharmacol. Ther. 16 (1993) 477-487.
18. Handley D.A., Development and therapeutic indications for PAF receptor antagonist. Drugs Future 13 (1988) 137-152.
19. Heath M.F., Evans R.J., Hayes L.J., Dextran-70 inhibits equine platelet aggregation induced by PAF but not by other agonists, Equine Vet. J. 30 (1998) 408-411.
20. Hellewell P.G., Williams T.J., Antagonism of PAF-induced oedema formation in rabbit skin: a comparison of different agonists, Br. J. Pharmacol. 97 (1989) 171.
21. Herbert J.M., Bernart A., Valette G., Gigo V., Lale A., Laplace M.C., Lespy L., Savi P., Maffrand J.P., Le Fur G., Biochemical and pharmacological activities of SR 27417, a highly potent, long acting platelet activating factor receptor antagonist, J. Pharmacol. Exp. Therapy 259 (1991) 44-51.
22. Herbert J.M., Valette G., Bernart A., Savi P., Maffrand J.P., Le Fur G., SR 27417, a highly potent, selective and long-acting antagonist of the PAF receptor, Drugs Future 17 (1992) 1011-1018.
23. Herbert J.M., Laplace M.C., Maffrand J.P., Bindind of [_H]SR 27417, a novel platelet-activating factor (PAF) receptor antagonist, to rabbit and human platelets and polymorphonuclear leukocytes, Biochem. Pharmacol. 45 (1993) 51-58.
24. Herbert J.M., Bernart A., Tibirica E., Effect of SR 27417, a novel PAF antagonist on antigen-induced hypotension in the rat, J. Lip. Mediators Cell Signal. 15 (1997) 115-123.
25. 2 and neutrophil in dogs, Arerugi 42 (1993) 1563-1568.
26. Kenakin T.P., Pharmacological analysis of drug receptor interaction, Raven, New York, 1987, pp. 210-217.
27. Lekeux P., Gustin P., Desmecht D., Linden A., Thérapeutique des pathologies respiratoires aiguës des bovins, Ann. Méd. Vét. 135 (1991) 175-184.
28. Leroy P., Farnir F., Méthodes Statistiques en Médecine Vétérinaire. Départment de Génétique, Faculté de Médecine Vétérinaire-Université de Liége, Belgique, 1998, pp. 251-257.
29. Livio M., Vigano G., Morigi M., Ubiali A., Galbusera M., Remuzzi G., Rôle of platelet-activating factor in primary hemostasis, Am. J. Physiol. 254 (1988) 1218-1223.
30. +, Genet. Pharmacol. 24 (1993) 461-469.
31. Ponpidom M.M., Hwang S.B., Doebber T.W., Acton J.J., Alberts A.W., Biftu T., Brooker D.R., Bugianesi R.L. Chabala J.C., Gamble N.L., Graham D.W, Wu M.S., ±-trans-2-(3-Methoxy-5-methylsulfonyl-4-propoxyphenyl)-5-(3-,4,5- trimethoxyphenyl) tetra hydrofuran (L-659-989), a novel, potent PAF receptor antagonist, Biochem. Biophys. Res. Comm. 150 (1988 ) 1213-1220.
32. Prescott S.M., Stafforini D.M., Zimmerman G.A., Mcintyre T.M., The natural history of PAF: from physiological regulator to pathological mediator, in: Proceedings 5th International Congress on Platelet-Activating Factor and Related Lipid Mediators, Berlin, 1995, p. 2.
33. Sagara H., Makino S., Fukuda T., PAF receptor antagonist in asthma therapy, Nippon Rinsho 54 (1996) 3056-3061.
34. Schorderet M., Pharmacologie des concepts fondamentaux aux applications thérapeutiques, Frison-Roché, Paris, Ed. Slaktine, 1988, pp. 3-19
35. Schumachcr W.A., Steinbacher T.E., Heran C.L., Megill J.R., Durham S.K., Effects of antithrombotic drugs in a rat model of aspirin-insensitive arterial thrombosis, Thromb. Haem. 69 (1993) 509-514.
36. Soloviev A.I., Braquet P., Platelet-activating factor - A potent endogenous mediator responsible for coronary vasospasm, News Physiol. Sci. (NIPS) 7 (1992) 166-172.
37. Terashita Z.I., Imura Y., Nishikawa K., Inhibition by CV-3988 of the binding of [_H]-platelet activating factor (PAF) to the platelets, Biochem. Pharmacol. 34 (1985) 1491-1495.
38. Van De Weerdt M.-L., Desmecht D., Lekeux P., Effect of platelet-activating factor on bovine pulmonary function, Vet. Rec. 16 (1997) 168-172.
39. Vargaftig B.B., PAF a mediator in search of a disease. Clin Rev. Allergy 12 (1994) 419-421.